Milestone Pharmaceuticals (MIST) Competitors $1.95 -0.02 (-1.02%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$2.00 +0.05 (+2.82%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST vs. ANAB, SIGA, SEPN, KROS, BCAX, SNDL, TERN, PVLA, ORGO, and GHRSShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include AnaptysBio (ANAB), Siga Technologies (SIGA), Septerna (SEPN), Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), SNDL (SNDL), Terns Pharmaceuticals (TERN), Palvella Therapeutics (PVLA), Organogenesis (ORGO), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry. Milestone Pharmaceuticals vs. Its Competitors AnaptysBio Siga Technologies Septerna Keros Therapeutics Bicara Therapeutics SNDL Terns Pharmaceuticals Palvella Therapeutics Organogenesis GH Research AnaptysBio (NASDAQ:ANAB) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Do institutionals & insiders have more ownership in ANAB or MIST? 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 33.5% of AnaptysBio shares are owned by insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor ANAB or MIST? In the previous week, AnaptysBio had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 9 mentions for AnaptysBio and 8 mentions for Milestone Pharmaceuticals. AnaptysBio's average media sentiment score of 1.32 beat Milestone Pharmaceuticals' score of 0.48 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Milestone Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ANAB or MIST? AnaptysBio presently has a consensus target price of $46.13, suggesting a potential upside of 137.76%. Milestone Pharmaceuticals has a consensus target price of $4.50, suggesting a potential upside of 130.77%. Given AnaptysBio's stronger consensus rating and higher possible upside, equities research analysts plainly believe AnaptysBio is more favorable than Milestone Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has more volatility and risk, ANAB or MIST? AnaptysBio has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Is ANAB or MIST more profitable? Milestone Pharmaceuticals has a net margin of 0.00% compared to AnaptysBio's net margin of -107.66%. AnaptysBio's return on equity of -366.98% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-107.66% -366.98% -30.58% Milestone Pharmaceuticals N/A -1,672.29%-83.09% Which has stronger earnings & valuation, ANAB or MIST? Milestone Pharmaceuticals has lower revenue, but higher earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M5.95-$145.23M-$4.48-4.33Milestone Pharmaceuticals$1M165.73-$41.52M-$0.84-2.32 SummaryAnaptysBio beats Milestone Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$167.44M$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-2.3221.1676.3926.51Price / Sales165.73446.35527.15123.58Price / CashN/A45.4037.1760.46Price / Book7.809.6213.306.29Net Income-$41.52M-$53.28M$3.28B$270.51M7 Day Performance14.04%1.01%0.88%1.95%1 Month Performance14.71%4.58%4.67%6.33%1 Year Performance27.45%8.35%76.59%25.62% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals2.4301 of 5 stars$1.95-1.0%$4.50+130.8%+28.3%$167.44M$1M-2.3230ANABAnaptysBio2.4305 of 5 stars$20.16-13.8%$46.13+128.8%-49.9%$655.13M$91.28M-4.50100News CoveragePositive NewsAnalyst ForecastHigh Trading VolumeSIGASiga Technologies1.4304 of 5 stars$9.00+0.9%N/A+12.5%$638.73M$138.72M7.9640SEPNSepterna1.611 of 5 stars$14.47+1.3%$26.75+84.9%N/A$636.68M$1.08M-1.43N/AKROSKeros Therapeutics3.3534 of 5 stars$15.55-0.7%$30.00+92.9%-71.6%$636.04M$3.55M50.16100Positive NewsBCAXBicara Therapeutics2.0221 of 5 stars$11.38-2.1%$32.25+183.4%-55.7%$634.02MN/A-3.5932SNDLSNDL3.6483 of 5 stars$2.50+3.7%$4.50+80.0%+16.3%$633.29M$671.81M-9.262,516TERNTerns Pharmaceuticals3.9906 of 5 stars$7.13-1.4%$15.61+118.9%-22.4%$632.71MN/A-6.8640Positive NewsPVLAPalvella Therapeutics2.142 of 5 stars$54.63-3.9%$60.91+11.5%N/A$628.63M$42.81M-4.51N/AORGOOrganogenesis3.9868 of 5 stars$4.96+0.6%$7.50+51.2%+69.9%$625.41M$429.31M-35.43950Positive NewsGHRSGH Research1.7034 of 5 stars$13.11+9.8%$32.00+144.1%+53.5%$621.22MN/A-17.7210Positive News Related Companies and Tools Related Companies ANAB Alternatives SIGA Alternatives SEPN Alternatives KROS Alternatives BCAX Alternatives SNDL Alternatives TERN Alternatives PVLA Alternatives ORGO Alternatives GHRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIST) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIST Stock Alerts